Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...

The "Molecular Switch Targeting Therapies Market Landscape, Innovation Pipeline and Commercial Impact 2026" report has been ...

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...

REGENXBIO Inc.  today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler ...

A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical ...

Researchers from Kumamoto University have developed a new peptide-based technology that enables insulin—normally injected—to be taken orally while still powerfully lowering blood sugar. Their ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the ...

Tiny self-propelled nanorobots use body chemistry to navigate directly to tumors and deliver cancer drugs more effectively.

New collaboration empowers customers with sequence-perfect constructs as long as 50 kb Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, and Ansa Biotechnologies, ...

Data from up to 42 months of treatment reinforce lucerastat's potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is finali ...